Daiichi Sankyo Co., Ltd.'s office in Brazil: ,
Business Address: Alameda Xingu, 766 - Alphaville Industrial, Barueri - SP, 06455-030,
Phone: +55 800 055 6596
E-mail: sac@dsbr.com.br
Web: https://www.daiichisankyo.com.br/site/fale-conosco/
| Native name | 第一三共株式会社 |
|---|---|
| Romanized name | Daiichi Sankyō kabushiki gaisha |
| Type | Public KK |
| Traded as | TYO: 4568 TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component |
| Industry | Pharmaceutical |
| Predecessors |
|
| Founded | Tokyo, Japan (2005) (by merger) |
| Headquarters | Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan |
| Key people |
|
| Products |
|
| Revenue |  $ 9.028 billion USD (FY 2019) (¥ 981.8 billion JPY) (FY 2019) |
| Net income | $ 1.276 billion USD (FY 2019) (¥ 138.8 billion JPY) (FY 2019) |
| Number of employees | 15,348 (as of March 2020) |
| Website | http://www.daiichisankyo.com |
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).